David Gaiero

Director of Finance/CFO en CYTEIR THERAPEUTICS, INC. .

Fortuna: 308 197 $ al 31/03/2024

45 años

Health Technology

Consumer Services

Perfil

David Gaiero is currently the Chief Financial Officer & Treasurer at Cyteir Therapeutics, Inc. He previously worked as the Chief Financial & Accounting Officer at Wave Life Sciences Ltd.
from 2017 to 2020 and as the Vice President & Global Controller at OvaScience, Inc. from 2015 to 2017.
Mr. Gaiero completed his undergraduate degree at the University of Massachusetts.

Participaciones conocidas en empresas públicas

Empresa	Fecha	Número de acciones	Valoración	Fecha de valoración
CYTEIR THERAPEUTICS, INC. 0.28%	04/03/2024	102 391 ( 0.28% )	308 197 $	31/03/2024

Cargos activos de David Gaiero

Empresas	Cargo	Inicio
CYTEIR THERAPEUTICS, INC.	Director of Finance/CFO	01/12/2020

Todos los cargos activos de David Gaiero

Antiguos cargos conocidos de David Gaiero.

Empresas	Cargo	Fin
WAVE LIFE SCIENCES LTD.	Director of Finance/CFO	04/12/2020
OvaScience, Inc. OvaScience, Inc. Pharmaceuticals: MajorHealth Technology OvaScience, Inc. engages in the research and development of female infertility treatments. Its portfolio includes AUGMENT, OvaPrime, OvaTure, and OvaXon which intends to improve the female's egg health and reserve. The company was founded by Rich H. Aldrich, Michelle Dipp, Jonathan L. Tilly, and Christoph H. Westphal on April 5, 2011 and is headquartered in Waltham, MA.	Comptroller/Controller/Auditor	01/01/2017

Ver el detalle de la experiencia de David Gaiero.

Formación de David Gaiero.

University of Massachusetts

Undergraduate Degree

Experiencias
Funciones ocupadas

Activas

Inactivas

Empresas cotizadas

Empresas privadas

Ver el detalle de la experiencia de David Gaiero.

Relaciones

Relaciones de 1er grado

Empresas vinculadas al 1er grado

Hombre

Mujer

Administradores

Ejecutivos

Consultar la red personal

Empresas relacionadas

Empresas cotizadas	2
WAVE LIFE SCIENCES LTD.	Health Technology
CYTEIR THERAPEUTICS, INC.	Health Technology

Empresas privadas	1
OvaScience, Inc. OvaScience, Inc. Pharmaceuticals: MajorHealth Technology OvaScience, Inc. engages in the research and development of female infertility treatments. Its portfolio includes AUGMENT, OvaPrime, OvaTure, and OvaXon which intends to improve the female's egg health and reserve. The company was founded by Rich H. Aldrich, Michelle Dipp, Jonathan L. Tilly, and Christoph H. Westphal on April 5, 2011 and is headquartered in Waltham, MA.	Health Technology